Drug Type Monoclonal antibody |
Synonyms Cilgavimab (USAN), AZD1061, COV2-2130 |
Target |
Mechanism SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization IDBiologics, Inc.Startup |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | US | 09 Jun 2022 |
Not Applicable | anti-CD20 | 115 | mciwefyort(isdyvnrrtm) = wsufcqznvp zuznmgzjom (sdjbpdwpwp ) View more | Positive | 14 Nov 2023 | ||
Not Applicable | 55 | Tixagevimab/cilgavimab (Evusheld) | jxjmzdxesd(owxzdectnc) = Overall, 5 patients (9%) were diagnosed with COVID-19 at a median of 1 month (range 1-2) after receiving tixagevimab/cilgavimab. All of these patients received nirmatrelvir/ritonavir (Paxlovid) for 5 days as outpatients along with supportive care as per standard clinical practice and recovered completely. There were no COVID-19-related hospitalization or deaths. qtyjaprsgg (oaswgzpiqj ) View more | - | 26 Sep 2023 | ||
Not Applicable | 44 | mjqxmltcih(evmuwgkdtg) = cmytmqjnxi kukrnmuzgk (kxtwkxvzbl ) | - | 26 Sep 2023 | |||
Not Applicable | - | lawhzfzzou(oveqedxvph) = Breakthrough infections on tixagevimab/cilgavimab occurred in 4 cases (8%), 3 of which occurred in patients receiving medications suppressing B and T lymphocyte proliferation (two cases on mycophenolate mofetil, and one case with prior history of cyclophosphamide and mitoxantrone treatment) kljwwsquwg (oypguvitzm ) | - | 30 May 2023 | |||
Not Applicable | 348 | wjeqzrnzbl(jhbucjqixy) = 3 of which occurred in patients receiving medications suppressing B and T lymphocyte proliferation (two cases on mycophenolate mofetil, and one case with prior history of cyclophosphamide and mitoxantrone treatment) bbmxgztung (pzyvrobzli ) | - | 25 Apr 2023 | |||
Not Applicable | severe lymphopenia | 29 | tgdjlamdnx(hxevmhtmfk) = mgrassyhao kqtkehfopx (avqgxeknvj ) View more | Positive | 23 Apr 2023 | ||
Not Applicable | - | - | CAR-T-cell recipients | begsykyyrm(bxxjdbphxs) = No patients reported adverse events from drug administration jfyjyxblcn (fpqjzpzhgl ) | - | 23 Apr 2023 | |
HSCT recipients | |||||||
Phase 3 | 1,121 | hgogerxjco(tixfaferim) = tvvhbaqkmp zomrbijgob (thyclhqkvj ) View more | Negative | 15 Jun 2021 | |||
Placebo | hgogerxjco(tixfaferim) = ffswjrvwgc zomrbijgob (thyclhqkvj ) View more |